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BACKGROUND: This double-blind, randomized controlled trial aimed to investigate inhaled budesonide and
oral dexamethasone compared with placebo for their prophylactic efﬁcacy against acute mountain sickness
after acute high-altitude exposure.
METHODS: There were 138 healthy young male lowland residents recruited and randomly assigned to receive
inhaled budesonide (200 mg, twice a day [bid]), oral dexamethasone (4mg, bid), or placebo (46 in each group).
They traveled to 3900 m altitude from 400 m by car. Medication started 1 day before high-altitude exposure
and continued until the third day of exposure. Primary outcome measure was the incidence of acute mountain
sickness after exposure.
RESULTS: One hundred twenty-four subjects completed the study (42, 39, and 43 in the budesonide,
dexamethasone, and placebo groups, respectively). Demographic characteristics were comparable among
the 3 groups. After high-altitude exposure, signiﬁcantly fewer participants in the budesonide (23.81%) and
dexamethasone (30.77%) groups developed acute mountain sickness compared with participants receiving
placebo (60.46%) (P ¼ .0006 and P ¼ .0071, respectively). Both the budesonide and dexamethasone
groups had lower heart rate and higher pulse oxygen saturation (SpO2) than the placebo group at altitude.
Only the budesonide group demonstrated less deterioration in forced vital capacity and sleep quality than
the placebo group. Four subjects in the dexamethasone group reported adverse reactions.
CONCLUSIONS: Both inhaled budesonide (200 mg, bid) and oral dexamethasone (4 mg, bid) were effective
for the prevention of acute mountain sickness, especially its severe form, compared with placebo. Bude-
sonide caused fewer adverse reactions than dexamethasone.
 2014 The Authors. Published by Elsevier Inc. All rights reserved.  The American Journal of Medicine
(2014) 127, 1001-1009
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tudes often suffer acute mountain sickness, a syndrome
caused by hypobaric hypoxia. It usually results in headache,
gastrointestinal symptoms, fatigue/weakness, dizziness/
lightheadedness, and difﬁculty in sleeping. These unpleasant
symptoms often cause impairment to health, life quality, andopen access article under the CC BY-NC-ND license
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life-threatening high-altitude cerebral edema or high-altitude
pulmonary edema if not treated adequately.1
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1002 The American Journal of Medicine, Vol 127, No 10, October 2014immediate and excessively rapid ascents as well as great
physical exertion. These characteristics may greatly in-
crease the occurrence and severity of acute mountain
sickness, posing a serious threat to health and life. After the
Yushu earthquake (4000 m on average, Qinghai Province,
China) in 2010, AMS incidence reached 80% among un-CLINICAL SIGNIFICANCE
 Inhaled budesonide, a drug mainly used
for the treatment of asthma and chronic
obstructive pulmonary disease, was proven
effective for the prevention of acute
mountain sickness after acute high-
altitude exposure but caused fewer
adverse reactions than dexamethasone.
 Budesonide alleviated the impairment
of high altitude on forced vital capa-
city, pulse oxygen saturation, and sleep
quality.acclimatized rescuers for earth-
quake relief work. Death was
even reported due to severe alti-
tude diseases. To “rescue the
rescuers” became a main task for
the medical teams there.2 Pain-
ful lessons were learned that high
attention should be paid to the
prevention of acute mountain sick-
ness under emergent conditions.
Gradual stagedascent canprevent
acute mountain sickness but is
impractical in emergency situations.
Acetazolamide and dexamethasone
can prevent acute mountain sickness
effectively.3-5 They are both recom-
mended by the Wilderness Medical
Society with a recommendation grade of 1A.6 Acetazolamide
has mild side effects.3,5 It is recommended to be started the day
before ascent.6 Its prophylactic efﬁcacy is not sufﬁcient dur-
ing excessively rapid ascents.7 Although oral dexamethasone
may cause systemic side effects,8-10 it should be considered
with priority when a very rapid effect is required, as, for
example, when rescue workers are called to ascend very
fast.11 The prevention of acute mountain sickness is more
important but more difﬁcult under emergent conditions.
Pulmonary function is often impaired in subjects who
develop acute mountain sickness, compared with healthy
ones at altitude.12,13 It is controversial whether acute moun-
tain sickness is related to interstitial pulmonary edema.12-16
The mechanisms underlying the prophylactic efﬁcacy of
dexamethasone are not fully understood, but some may be
related to the lung, such as upregulating alveolar apical
membrane Naþ channel and basolateral Naþ-Kþ-
ATPase,17,18 stimulating surfactant secretion,19 preventing
pulmonary transvascular protein escape,20 and enhancing the
integrity of airway epithelia barrier.21 Budesonide, an inhaled
glucocorticoid with few systemic side effects, can improve
pulmonary function of asthmatic patients. After being
inhaled, budesonide may generate similar effects on the lung
as dexamethasone, thus preventing acute mountain sickness.
The objective of this study was to investigate inhaled
budesonide and oral dexamethasone compared with placebo
for their prophylactic efﬁcacy against acute mountain sick-
ness after acute high-altitude exposure.
METHODS
Trial Design
This was a prospective, multi-arm, single-center, double-
blind, randomized controlled trial.Participants
Eligible participants had to be non-Tibetan healthy young
male lowland residents (18-35 years old). Participants with
any one of the following conditions were excluded: high-
altitude (>2500 m) exposure history in the past year; se-
vere organic diseases; contraindications of budesonide ordexamethasone; other unsuitable
conditions (Appendix, sections
How were the participants re-
cruited? and Details about exclu-
sion criteria, available online).Ethics Statement
This study was approved by the
Ethics Committee of Xinqiao
Hospital, the Second Clinic Med-
ical College of the Third Military
Medical University. Written in-
formed consent was obtained from
all subjects before study initiation.
All clinical investigation obeyed
the Declaration of Helsinki. Trialregistration: Chinese Clinical Trial Registry, ChiCTR-PRC-
13003296.
Randomization
An independent physician randomly assigned the subjects
to 3 groups: the budesonide, dexamethasone, and placebo
groups, using a computer-generated random number list
with an allocation ratio of 1:1:1 (Appendix, Section Why is
dexamethasone rather than acetazolamide used as a positive
control? available online).
Interventions
Medication. The budesonide group received oral starch
tablets plus inhalation of budesonide (200 mg, twice a
day [bid]; in a dry powder inhaler; AstraZeneca AB,
Södertälje, Sweden). The dexamethasone group received
empty inhalers plus dexamethasone tablets (4 mg, bid;
Guangdong Zhongsheng Pharmaceutical Co., Ltd.,
China). The placebo group received both inhaled and oral
placebos (Appendices 4-7, available online).
Medication started 1 day before high-altitude (>2500 m)
exposure and continued until the third day of exposure.
Other personal medications were not allowed (Appendix 8,
available online).
The subjects were aware of the main side effects of
budesonide and dexamethasone. It was suggested that they
discontinue medication and inform the researchers if there
were any adverse reactions. During medication, the subjects
were instructed in the correct way of inhalation.
High-Altitude Exposure and Examinations. Demo-
graphic data were collected during recruitment. Baseline
examinations were performed at sea level (Chongqing,
Zheng et al Budesonide at High Altitude 1003China, 400 m). Then the subjects traveled to Litang County,
Sichuan Province, China (3900 m) from Chongqing by car
on July 3, 2013. On July 4, they acutely ascended to 2600 m
from 650 m, which was deﬁned as the earliest time of high-
altitude exposure. They reached the destination at 3900 m
on July 8. Symptoms related to acute mountain sickness,
heart rate, and pulse oxygen saturation (SpO2) were recor-
ded at 96 hours after high-altitude exposure. Spirometry and
sleep questionnaire were completed at 144 and 168 hours,
respectively (Figure 1).Outcome Measures
Primary outcomemeasure was the incidence of acute mountain
sickness at altitude. Secondary outcome measures were as fol-
lows: the incidence of its severe form, its severity reﬂected by
Lake Louise Scoring System (LLS) score,22,23 heart rate, SpO2,
spirometric parameters, sleep quality assessed by question-
naires, and adverse reactions related to the investigational drugs.
Diagnostic Criterion. Acute mountain sickness was diag-
nosed by LLS,22,23 which includes 5 self-reporting symptoms:
headache, gastrointestinal symptoms, fatigue/weakness,
dizziness/lightheadedness, and difﬁculty in sleeping. Each
symptom is scored 0-3, with 0 indicating none and 1-3 in-
dicating mild, moderate, and severe, respectively. Acute
mountain sickness is deﬁned by a total score of 3 or more in
the presence of headache. Its mild form has a score of 3-4,
while its severe form has a score of 5 or more.
Heart Rate and SpO2. Heart rate and SpO2 were examined
by pulse oximeters (Nonin Onyx 9550; Nonin Medical,
Inc., Plymouth, Minn).
Spirometry. Forced vital capacity (FVC), FVC %Pred.
(percentage of the predicted value), forced expiratory vol-
ume in one second (FEV1), and FEV1 %Pred. wereFigure 1 Ascent proﬁle, medication and exam
Scoring System; SpO2 ¼ pulse oxygen saturatioachieved with a portable spirometer (Minato AS-507;
Minato Medical Science Co., Ltd., Osaka, Japan). Their
difference values between sea level and altitude were
computed. Spirometry was performed according to the
guidelines of the American Thoracic Society.24
Sleep Questionnaire. The Pittsburgh Sleep Quality Index
(PSQI)25 and Epworth sleepiness scale (ESS)26 were
included in the sleep questionnaire.
The PSQI has 19 self-rating questions that evaluate sleep in
7 areas: subjective sleep quality, sleep latency, sleep duration,
habitual sleep efﬁciency, sleep disturbances, use of sleeping
medication, and daytime dysfunction. Each area is scored 0-3,
with 3 reﬂecting the negative extreme. The sum of their scores
yields the global PSQI score. TheChinese version of PSQI is a
sensitive, reliable, and valid tool to assess sleep quality.27We
adopted its 1-week version considering our follow-up plan.
Because other medications were prohibited, we did not
include “use of sleeping medication” in the total score.
ESS measures the chance of dozing off or falling asleep
in 8 situations to reﬂect daytime somnolence status. Each
situation is scored 0-3, with 3 representing the highest
chance of dozing. The ESS score is the sum of them.
Sample Size
The placebo group was assumed to have the highest inci-
dence of 60%. According to published studies concerning
dexamethasone and our previous pilot trial concerning
budesonide, the lowest incidence was assumed to be 25%.
Assuming s ¼ 0.05, 1-b ¼ 0.8, and considering a dropout
rate of 20%, we calculated the sample size to be 138 cases
(46 in each group) (Appendix 9, available online).
Blinding
Empty inhalers could not be distinguished from budesonide
inhalers by vision or feel. Starch tablets were similar toinations at altitude. LLS ¼ Lake Louise
n.
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pendent physician mentioned above repackaged these
drugs in medicine boxes for each subject and reserved the
blinding code. The subjects, researchers, and other physi-
cians were blinded (Appendix 10, available online).Statistical Methods
One-way analyses of variance followed by Student-
Newman-Keuls tests were used to compare weight, height,
heart rate, SpO2, and the difference value of FVC and FEV1
among the 3 groups. Paired sample t tests were used to
compare heart rate, SpO2, FVC, and FEV1 between lowland
and altitude in each group. Kruskal-Wallis tests followed
by Nemenyi tests were applied to compare age, body mass
index, smoking and drinking history, LLS score, and items
of sleep questionnaire among the 3 groups. Paired sample
Wilcoxon signed-rank tests were applied to compare items
of sleep questionnaire between lowland and altitude in each
group. The incidences of acute mountain sickness and its
severe form were compared among the 3 groups using chi-
squared tests. All tests were 2-tailed. Differences were
considered statistically signiﬁcant if P < .05, except when
Bonferroni method was used. The statistical analysesFigure 2 Flow diagrwere performed using SPSS 13.0 for Windows (SPSS Inc.,
Chicago, Ill).RESULTS
Participant Flow
There were 138 eligible participants recruited at Chongqing,
China (46 in each group after randomization). Before
intervention, 10 subjects were lost to follow-up due to
personal reasons (4, 3, and 3 in the budesonide, dexa-
methasone, and placebo groups, respectively). During
intervention, 4 participants in the dexamethasone group
encountered adverse reactions and discontinued medication
before receiving any examination at altitude. Finally, 124
subjects completed the trial, whose data were included in
analyses (42, 39, and 43 in the budesonide, dexamethasone,
and placebo groups, respectively). Intension-to-treat anal-
ysis could not be used (Figure 2).Demographic Data
There were no signiﬁcant differences in demographic data
among the 3 groups, including age, weight, height, and bodyam of the study.
Table 1 Demographic Data of the Subjects in the 3 Groups
Variable
Budesonide
n ¼ 46
Dexamethasone
n ¼ 46
Placebo
n ¼ 46 P Value
Age, mean  SD, years 20.39  2.40 20.78  2.30 20.52  2.35 .562
Weight, mean  SD, kg 63.91  7.68 61.83  7.18 62.07  6.86 .322
Height, mean  SD, cm 173.09  5.17 170.89  4.23 172.03  4.95 .094
BMI, mean  SD 21.32  2.28 21.13  1.86 20.95  1.95 .739
Smoking history .669
Never, n (%) 11 (23.91) 8 (17.39) 12 (26.09)
Occasionally, n (%) 6 (13.04) 12 (26.09) 8 (17.39)
Mild, n (%) 26 (56.52) 19 (41.30) 24 (52.17)
Moderate, n (%) 2 (4.35) 5 (10.87) 1 (2.17)
Severe, n (%) 1 (2.17) 2 (4.35) 1 (2.17)
Drinking history .400
Never, n (%) 42 (91.30) 45 (97.83) 43 (93.48)
Mild, n (%) 4 (8.70) 1 (2.17) 2 (4.35)
Moderate, n (%) 0 (0.00) 0 (0.00) 1 (2.17)
Severe, n (%) 0 (0.00) 0 (0.00) 0 (0.00)
BMI ¼ body mass index.
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(Table 1).The Incidence and Severity of Acute
Mountain Sickness
After high-altitude exposure, signiﬁcantly fewer partici-
pants in the budesonide (23.81%) and dexamethasone
(30.77%) groups developed acute mountain sickness,
compared with participants receiving placebo (60.46%)
(P ¼ .0006 and P ¼ .0071, respectively). Relative risks for
budesonide and dexamethasone compared with placebo
were 0.394 (95% conﬁdence interval [CI], 0.218-0.712)
and 0.509 (95% CI, 0.300-0.864), respectively. Difference
between the budesonide and dexamethasone groups was
not signiﬁcant (Figure 3).
At altitude, the incidences of severe acute mountain
sickness in the budesonide (4.76%) and dexamethasone
(7.69%) groups were both signiﬁcantly lower than the pla-
cebo group (39.53%) (P ¼ .0001 and P ¼ .0008, respec-
tively). Relative risks for budesonide and dexamethasone
compared with placebo were 0.120 (95% CI, 0.030-0.489)
and 0.195 (95% CI, 0.062-0.613), respectively (Figure 3).
LLS scores in the budesonide (1.64  1.65) and dexa-
methasone (1.92  1.72) groups were both signiﬁcantly
lower than the placebo group (3.42  2.30) (P ¼ .0011 and
P ¼ .0144, respectively).Figure 3 Incidences of acute mountain sickness (mild, severe
and total) after high-altitude exposure in the 3 groups. *Sig-
niﬁcant difference of the total incidence of acute mountain
sickness compared with the placebo group. #Signiﬁcant dif-
ference of the incidence of severe acute mountain sickness
compared with the placebo group.Heart Rate and SpO2
Baseline measurements of heart rate and SpO2 did not differ
among the 3 groups. Heart rate was elevated at altitude
compared with sea level in every group (all P < .001). Both
the budesonide and dexamethasone groups had lower heart
rate than the placebo group at altitude (both P < .05)
(Figure 4A).SpO2 went down at altitude compared with sea level in
every group (all P < .001). Both the budesonide and
dexamethasone groups had higher SpO2 than the placebo
group at altitude (both P < .05) (Figure 4B) (Appendix 11,
available online).
Figure 4 (A) Heart rate and (B) pulse oxygen saturation (SpO2) at sea level and altitude
in the 3 groups.
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Spirometric parameters were similar among the 3 groups at
sea level. In every group, FVC and FVC %Pred. dropped
after high-altitude exposure, while FEV1 and FEV1 %Pred.
did not change signiﬁcantly. The budesonide group had
signiﬁcantly smaller DFVC and DFVC %Pred. (degree of
decrement) than the placebo group (both P < .05), while
dexamethasone versus placebo or dexamethasone versus
budesonide showed no signiﬁcant difference (Table 2).Table 2 Spirometric Parameters at Sea Level and Altitude, and their
Variable
Mean  SD
Budesonide
n ¼ 41*
Dexamethasone
n ¼ 39
Place
n ¼
Sea level
FVC, L 4.35  0.45 4.31  0.37 4.
FVC %Pred., % 99.85  8.68 99.54  7.26 100.
FEV1, L 3.65  0.35 3.68  0.30 3.
FEV1 %Pred., % 83.24  6.45 83.90  6.38 83.
Altitude
FVC, L 4.23  0.47 4.11  0.44 4.
FVC %Pred., % 97.05  9.15 94.97  9.51 93.
FEV1, L 3.63  0.39 3.65  0.39 3.
FEV1 %Pred., % 82.71  6.82 83.23  8.66 82.
Altitude - Sea level
FVC, L -0.13  0.34¶ -0.19  0.27¶ -0.
FVC %Pred., % -2.80  7.60¶ -4.56  6.45¶ -6.
FEV1, L -0.02  0.26 -0.03  0.20 -0.
FEV1 %Pred., % -0.54  5.84 -0.67  4.64 -1.
FEV1 ¼ forced expiratory volume in one second; FVC ¼ forced vital capacity
*One case was excluded for poor quality of test.
†P value of the difference among the 3 groups.
‡P value of the difference between budesonide and dexamethasone.
§P value of the difference between budesonide and placebo.
kP value of the difference between dexamethasone and placebo.
¶P < .05 for paired sample tests between sea level and altitude in one groSleep Quality
ESS score, global PSQI score, and sub-scales of PSQI
did not differ among the 3 groups at sea level. Comparisons
of the difference value of each item among the 3 groups
showed that the budesonide group was better than the pla-
cebo group in subjective sleep quality, sleep latency, sleep
duration, and global PSQI score. Dexamethasone versus
placebo and budesonide versus dexamethasone had no sig-
niﬁcant difference (Table 3).Difference Values in the 3 Groups
bo
42* P value†
P Value of Post Hoc Tests
P12‡ P13§ P23k
34  0.51 .888 — — —
00  10.05 .971 — — —
67  0.40 .913 — — —
50  8.03 .916 — — —
04  0.48 .170 — — —
17  8.76 .158 — — —
61  0.39 .906 — — —
24  7.24 .841 — — —
30  0.30¶ .041 >.05 <.05 >.05
83  7.04¶ .037 >.05 <.05 >.05
06  0.25 .785 — — —
26  5.82 .814 — — —
; %Pred. ¼ percentage of the predicted value.
up.
Table 3 The Difference Values of Items of the PSQI and ESS in the 3 Groups
Items, mean  SD
Budesonide
n ¼ 42
Dexamethasone
n ¼ 39
Placebo
n ¼ 43 P Value*
P Value of Post Hoc Tests
P12† P13‡ P23§
Subjective sleep quality 0.14  0.81 0.05  0.69 0.40  0.90k .011 .9392 .0208 .0598
Sleep latency 0.60  0.77k 0.41  0.75k 0.05  1.05 .028 .5244 .0280 .3342
Sleep duration 0.21  0.92 0.28  0.72k 0.60  0.85k .019 .9593 .0354 .0803
Habitual sleep efﬁciency 0.05  0.94 0.13  0.61 0.26  1.05 .247 — — —
Sleep disturbances 0.10  0.66 0.00  0.51 0.09  0.81 .404 — — —
Daytime dysfunction 0.17  0.93 0.36  0.84k 0.56  1.05k .072 — — —
Global PSQI Score 0.40  3.08 0.31  2.15 1.86  3.93k .002 .6215 .0029 .0598
ESS score 0.43  6.44 0.31  4.50 1.07  5.70 .380 — — —
ESS ¼ Epworth sleepiness scale; PSQI ¼ Pittsburgh Sleep Quality Index.
*P value of the difference among the 3 groups.
†P value of the difference between budesonide and dexamethasone.
‡P value of the difference between budesonide and placebo.
§P value of the difference between dexamethasone and placebo.
kP < .05 for paired sample tests between sea level and altitude in one group.
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Four subjects in the dexamethasone group reported persis-
tent belching after receiving medication for 2 days. They
stopped medication and withdrew. No subjects in the
budesonide and placebo groups reported adverse reactions
related to the investigational drugs.DISCUSSION
Key Findings
Dexamethasone is recommended for the prevention of acute
mountain sickness by the Wilderness Medical Society with a
recommendation grade of 1A,6 but may cause systemic side
effects.8-10 In this study, we compared inhaled budesonide,
oral dexamethasone, and placebo for the prevention of acute
mountain sickness after acute high-altitude exposure. The
results showed that both budesonide and dexamethasone
were superior to placebo, resulting in about a 50% reduction
in the incidence, mostly of the severe form. Budesonide had
fewer side effects than dexamethasone and caused fewer
dropouts. Both budesonide and dexamethasone alleviated the
decrement of oxygenation and the increase of heart rates, but
only budesonide demonstrated slightly less deterioration in
FVC and sleep quality at high altitude.Possible Mechanisms
The pathogenesis of acute mountain sickness is not com-
pletely understood, but the lung appears to be involved as
evidenced by the fact that when compared with healthy
subjects at altitude, those who develop acute mountain
sickness tend to have lower SpO2, lower pulmonary
diffusing capacity, and higher alveolar-arterial oxygen
pressure difference.12,13 The alveolar space by analysis of
bronchoalveolar lavage ﬂuid appears not to be involved.28
Yet it is controversial whether acute mountain sickness isrelated to interstitial pulmonary edema12-16 or pulmonary
artery pressure.15,16
Peak serum concentrations of inhaled budesonide are
much lower than dexamethasone.29-31 Budesonide also has a
shorter half-life period than dexamethasone. This indicates
that budesonide is not acting solely through systemic ef-
fects. Its local effects in the lung may be of greater
importance.
The mechanisms underlying the prophylactic efﬁcacy
against acute mountain sickness of dexamethasone are not
fully understood. Some may have relation to the lung, such
as upregulating alveolar apical membrane Naþ channel and
basolateral Naþ-Kþ-ATPase,17,18 stimulating surfactant
secretion,19 preventing pulmonary transvascular protein
escape,20 and enhancing the integrity of airway epithelia
barrier.21 How any of these relate to the systemic symptoms
of acute mountain sickness remains to be uncovered.
In our study, budesonide caused less decreased in FVC
and its percent predicted value. Dexamethasone also had a
similar but nonsigniﬁcant trend. Both budesonide and
dexamethasone reduced the decrement of SpO2. This may
be a result of pulmonary function improvement, and may
be related to the mechanisms described above.
According to these ﬁndings, we speculate that budeso-
nide, an inhaled glucocorticoid, may generate similar but
more potent local effects on the lung than dexamethasone,
to improve the function of alveolar and airway epithelia,
thus improving pulmonary function, increasing SpO2, and
preventing acute mountain sickness.
Sleep is often disturbed at altitude.32 Nocturnal periodic
breathing is common and disruptive to sleep.33 A recent
study on high-altitude pulmonary edema-susceptible sub-
jects showed that prophylactic dexamethasone taken before
ascent prevented severe hypoxemia and sleep distur-
bances.34 According to our exploration based on subjective
questionnaires, inhaled budesonide effectively alleviated the
impairment of high altitude on sleep quality. However, we
1008 The American Journal of Medicine, Vol 127, No 10, October 2014did not utilize polysomnography. Whether budesonide af-
fects nocturnal breathing and sleep architecture at altitude
needs further exploration.Limitations
We traveled to high altitude by car, which is not as “acute”
compared with traveling by air. However, an incidence up to
60.46% in the placebo group suggests that the protection
from this staged ascent is insigniﬁcant. We chose young
male lowland residents as our target population because
they comprise the majority of people to fulﬁll emergency
tasks at altitude, during which immediate and excessively
rapid ascent is often necessary. Therefore, our results cannot
be extended to populations of other ages or females. We
could not include an acetazolamide group, which may also
be a limitation. However, we think it acceptable to include
dexamethasone instead, because it also has a recommenda-
tion grade of 1A and should be considered with priority
when a very rapid effect is required. Furthermore, studying
2 steroids, one largely limited to the lung and the other
acting elsewhere in the body, may give some insight into the
mechanisms underlying how corticosteroids are beneﬁcial at
high altitude.CONCLUSION
In this randomized controlled trial, we innovatively demon-
strated that both inhaled budesonide (200 mg, bid) and oral
dexamethasone (4 mg, bid) were effective for the prevention
of acute mountain sickness after acute high-altitude expo-
sure compared with placebo. Inhaled budesonide causes
fewer adverse reactions than oral dexamethasone. Budeso-
nide had favorable effects on FVC and SpO2 at altitude,
which may be related to the mechanisms underlying its
prophylactic efﬁcacy. It also beneﬁted sleep quality, which
is often disturbed at altitude. All these advantages of inhaled
budesonide make it a promising alternative for the preven-
tion of acute mountain sickness.
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Double dummy placebos were used to guarantee blinding:
Group Inhalers þ Tablets
Budesonide group: Budesonide inhalers þ Starch tablets
Dexamethasone group: Empty inhalers þ Dexamethasone
tablets
Placebo group: Empty inhalers þ Starch tablets
1009.e1 The American Journal of Medicine, Vol 127, No 10, October 2014APPENDIX
1. Why is a placebo group included? How were the
safety and rights of them guaranteed?
Budesonide had not been evaluated for prophylaxis
against acute mountain sickness before. The study compared
the investigational drug (budesonide), a positive control
(dexamethasone), and a placebo control to obtain more in-
formation. We think it necessary to include a placebo group
for the study.
Acute mountain sickness is a mild form of altitude
illness. High-altitude cerebral edema and high-altitude pul-
monary edema are more dangerous. The ascent proﬁle was
not that “acute” compared with traveling to a very high
altitude by air. Passive ascending by car had less physical
exhaustion compared with ascending on foot. The proba-
bility for severe altitude illnesses could be very low. During
the study, health care was monitored by a medical team to
prevent serious altitude illnesses. We also had an emergency
plan to cope with serious cases if there were any, including
oxygenation, immediate descent, drug therapy, and transfer
to local medical institutions. So the safety of the placebo
group was guaranteed.
Before signing written informed consents, the partici-
pants were aware of the purpose and process of the study,
and knew that they could be assigned to any of the 3 groups,
including the placebo group. They were also educated about
high altitude illnesses and the investigational drugs. The
participants had the right to quit this trial at any time if they
wished. So the rights of the placebo group were guaranteed.
2. Why is dexamethasone rather than acetazolamide
used as a positive control?
1) Both dexamethasone and acetazolamide can prevent
acute mountain sickness. Comparisons between them
have different conclusions, because different dexameth-
asone dosing, ascent proﬁles, and evaluation criteria may
confound results. Because most cases only have mild
acute mountain sickness and acetazolamide helps with
acclimatization, acetazolamide is considered with prior-
ity. But it may not be sufﬁcient to prevent acute moun-
tain sickness when excessively fast ascent proﬁles are
used.1 The side effects of dexamethasone limit its
application, thus it is not considered with priority in or-
dinary cases. Exceptions are if acetazolamide is contra-
indicated or when a very rapid effect is required, as, for
example, when rescue workers are called to ascend very
fast.2 The prophylactic efﬁcacy of dexamethasone is
established, and it also has a recommendation grade of
1A by the Wilderness Medical Society.3 So we think it
acceptable to include dexamethasone as a positive
control.
2) The mechanisms underlying the prophylactic efﬁcacy
of dexamethasone are not fully understood. Studying
2 steroids, one largely limited to the lung and the other
acting elsewhere in the body, may give some insight into
the mechanisms underlying how corticosteroids are
beneﬁcial at high altitude.3) Our target population is young male lowland residents,
who comprise the majority of people to fulﬁll emergency
tasks at altitude, such as rescue work and military tasks.
Under these emergent conditions, immediate and exces-
sively rapid ascent is often necessary, and dexametha-
sone has to be considered with priority even though it has
more side effects.2
3. How were the participants recruited?
The participants went to high altitude not only for the
study, but also to fulﬁll tasks at altitude. They were recruited
at Chongqing city (400 m). The study was not advertised.
We got in touch with them through introduction from their
leaders.
4. Details about exclusion criteria.
“Severe organic diseases” include heart, liver, or kidney
dysfunction; malignant tumor; and psychological or neuro-
logical disorder. “Other unsuitable conditions” mainly relate
to management convenience, for example, whether the
participant could follow our arrangements at altitude.
5. Why were empty inhalers used as inhaled
placebos?
The empty inhalers had the same appearance as bude-
sonide inhalers, but contained no drug powder. So only air
was inhaled. Pulmicort Turbuhaler (AstraZeneca, London,
UK) has rather ﬁne drug powder, and the volume of each
inhalation is rather small, so that one do not feel or taste any
medication when inhaling. We were sure that the subjects
could not distinguish the empty inhalers from budesonide
inhalers by vision, feel or taste.
6. Details about the inhaled placebo.
Drug powder was removed from the Pulmicort Tur-
buhaler to make the empty inhalers. This process was per-
formed in an operating room in Xinqiao Hospital. After that,
the empty inhalers were irradiated by 60Co to be sterilized in
the irradiation center of the Third Military Medical Uni-
versity. Attention was paid to make sure that the empty
inhalers looked the same as budesonide inhalers. For
example, to remove the drug powder, the packing box had
to be opened, and the plastic label circling the cylindrical
inhaler had to be removed. So packing boxes, manuals, and
plastic labels were removed for both budesonide and empty
inhalers. For another example, the appearance of inhalers
must not be hurt.
7. Details about the oral placebo.
Starch tablets were produced by Chongqing Pharma-
ceutical Research Institute Co., Ltd., China to be the same to
dexamethasone tablets in shape, size and color. They were
Table S1 Heart Rate and SpO2 at Sea Level and Altitude
Variables
Mean  SD
Budesonide
n ¼ 42
Dexamethasone
n ¼ 39
Placebo
n ¼ 43 P Value*
P Value of Post Hoc Tests
P12† P13‡ P23§
Sea level
Heart rate, beats per min 70.38  8.64 71.33  9.28 71.88  9.14 .658 — — —
SpO2, % 97.48  0.92 97.56  0.94 97.19  0.93 .065 — — —
Altitude
Heart rate, beats per min 83.38  10.42 83.59  10.76 90.23  12.04 .007 >.05 <.05 <.05
SpO2, % 89.31  2.57 88.49  2.42 86.3  3.31 <.001 >.05 <.05 <.05
SpO2 ¼ pulse oxygen saturation.
*P value of the difference among the 3 groups.
†P value of the difference between budesonide and dexamethasone.
‡P value of the difference between budesonide and placebo.
§P value of the difference between dexamethasone and placebo.
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8. Details about dosing regimen.
The medication period is clearly shown in Figure 1. The
ﬁrst time for medication in a day was after breakfast and the
second after dinner. The usage and dosage of both placebos
were the same as the investigational drugs, respectively.
Besides, although one budesonide inhaler contains 200
inhalations (100 mg in each inhalation), which is far more
than the amount actually needed for one participant (16
inhalations in total), we insisted one inhaler for one
person, because the lip of a person touches the suction
nozzle during inhalation.
9. Details about sample size estimation.
Formula for hypothesis testing of overall rates among
multiple groups of completely random design was used for
sample size estimation:
n ¼ 2l
.
2 sin1
ﬃﬃﬃﬃﬃﬃﬃﬃﬃ
pmax
p  2 sin1 ﬃﬃﬃﬃﬃﬃﬃﬃpmin
p 2
We took a ¼ 0.05, b ¼ 0.2. Since there were 3 groups,
the degree of freedom was 2. So l0.05, 0.2(2) ¼ 9.63. We
hypothesized that the placebo group would have an inci-
dence of 60%, and took pmax ¼ 0.6. According to published
literature and our previous pilot trial, both the budesonide
and dexamethasone groups were assumed to have an inci-
dence of 25%. So we took pmin ¼ .25. We calculated to
have nz 37. Considering a dropout rate of 20%, we ﬁnally
decided to include 138 subjects, with 46 in each group.
The incidences of acute mountain sickness pretreated with
budesonide or dexamethasone may be similar. Sample size
could be much larger than now for a noninferiority trial.
Therefore, this studywasnot designed to pay toomuchattention
to the comparison between budesonide and dexamethasone.
So far, different studies concerning high altitude may
adopt different ascent proﬁles, dosing regimen of dexa-
methasone, and even evaluation criterion (many earlier
studies used Environmental Symptoms Questionnaire).
Therefore, sample size estimation can be quite inaccurate.10. How was blinding guaranteed?
The independent physician did only 2 things in this
study: randomization and repackaging of drugs. He was not
involved in other parts of the study, such as study design,
recruitment, data collection, and health care.
1) Randomization:
The physician used a computer-generated random num-
ber list to allocate the subjects into 3 groups independently.
He reserved the blinding code, so the grouping information
was not available to the researchers, the subjects and other
physicians for health care.
2) Repackaging of drugs:
The researchers gave the 4 kinds of investigational drugs
(budesonide inhalers, empty inhalers, dexamethasone tab-
lets, and starch tablets) to the independent physician
mentioned above to be repackaged. The repackaging pro-
cess was completed by the physician alone according to the
grouping information that he created. He prepared one
medicine box for each subject. The serial number and name
of a subject were written on his box, and the drugs he should
receive were put into it. After repackaging, the physician
gave these medicine boxes to the researchers.
After these 2 processes, blinding was guaranteed.
11. Absolute values of heart rate and pulse oxygen
saturation.
